<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-ZUMLQKJE</identifier><date>2011</date><creator>Obradović, Marko</creator><relation>documents/doc/Z/URN_NBN_SI_doc-ZUMLQKJE_001.htm</relation><relation>documents/doc/Z/URN_NBN_SI_doc-ZUMLQKJE_001.pdf</relation><relation>documents/doc/Z/URN_NBN_SI_doc-ZUMLQKJE_001.txt</relation><format format_type="issue">2</format><format format_type="volume">62</format><format format_type="type">article</format><format format_type="extent">str. 63-71</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">262561536</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-ZUMLQKJE</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">farmakoekonomika</subject><subject language_type_id="slv">farmakogenomika</subject><subject language_type_id="slv">genotipizacija</subject><subject language_type_id="slv">stroški</subject><title>Farmakoekonomika v povezavi s farmakogenomiko</title><title>Pharmacoeconomic aspects of pharmacogenomics</title></Record>